Annotation Detail
Information
- Associated Genes
- FCGR2A
- Associated Variants
-
FCGR2A p.His167Arg (p.H167R)
(
ENST00000699278.1,
ENST00000367972.8,
ENST00000699277.1,
ENST00000271450.12,
ENST00000699279.1 )
FCGR2A p.His167Arg (p.H167R) ( ENST00000271450.12, ENST00000367972.8, ENST00000699277.1, ENST00000699278.1, ENST00000699279.1 ) - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- 1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.
- Variant Origin
- Common Germline
- Variant Origin
- Common Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1088
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1842
- Variant URL
- https://civic.genome.wustl.edu/links/variants/456
- Rating
- 4
- Evidence Type
- Prognostic
- Disease
- Breast Cancer
- Evidence Direction
- Does Not Support
- Evidence Level
- B
- Clinical Significance
- N/A
- Pubmed
- 24989892
Drugs